Analyst Price Targets — PDSB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 12, 2024 7:32 am | Mayank Mamtani | B.Riley Financial | $9.00 | $2.76 | StreetInsider | PDS Biotechnology Corp (PDSB) PT Lowered to $9 at B.Riley |
| March 28, 2024 7:41 am | Mayank Mamtani | B.Riley Financial | $11.00 | $3.85 | StreetInsider | PDS Biotechnology Corp (PDSB) PT Lowered to $11 at B.Riley on 1+ year delay |
Latest News for PDSB
PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript
Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs
PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter and year ended December 31, 2025, and will provide a clinical…
Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PDSB.
U.S. House Trading
No House trades found for PDSB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.